Fig 1: Illustration of the best docking score solution for Bcl-2 (utilizing the chosen crystal structure of 5JSN) with (A) CIS, (B) MEF, (C) CIS-MEF, and (D) CIS-NMEF along with the ligand mapping depicting various chemical bonds in Discovery Studio
Fig 2: Effect of Cisplatin (CIS), mefloquine (MEF), niosomal mefloquine (NMEF), and their combinations (MEF + CIS and NMEF + CIS) on (A) angiogenesis mediators (VEGF, KDR) (corresponding to Fig. 7), (B) apoptotic gene expression (Bax, Bcl-2, CASP3, CASP8) (corresponding to Fig. 8), and (C) apoptotic protein levels (Bax, Bcl-2, CASP3, CASP8) (corresponding to Fig. 9). Data demonstrate the synergistic modulation of key pathways by combination treatments, particularly NCIS-MEF
Fig 3: Effect of Cisplatin (CIS), mefloquine (MEF), niosomal mefloquine (NMEF), and combination (MEF + CIS and NMEF + CIS) on mean level of apoptotic mediators (Bax, Bcl-2, CASP3, and CASP8), (*** in comparison with UC (P < 0.001))(### comparassion between single theraphy and combination (P < 0.001))
Fig 4: Effect of Cisplatin (CIS), mefloquine (MEF), niosomal mefloquine (NMEF) and combination (MEF + CIS and NMEF + CIS) on gene expression of apoptotic mediators (Bax, Bcl-2, CASP3 and CASP8), (*** in comparison with UC (P < 0.001))(### comparassion between single theraphy and combination (P < 0.001))
Supplier Page from MyBioSource.com for Phospho-BCL-2 (Thr56) Colorimetric Cell-Based ELISA Kit